Trial Profile

A Single-arm, Prospective, Open-label Clinical Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 24 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Disitamab vedotin (Primary) ; Pyrotinib (Primary) ; Tislelizumab (Primary)
Indications Colorectal cancer
Focus Therapeutic Use

16 May 2022 Planned End Date changed from 20 Apr 2026 to 20 Jun 2026.
16 May 2022 Planned primary completion date changed from 20 Apr 2025 to 20 Jun 2025.
16 May 2022 Planned initiation date changed from 20 Apr 2022 to 20 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com